Insulet (PODD) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Insulet (PODD) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.76 Bn | 175.16 Bn | 7.27 Bn | -9.45% |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn | -16.59% |
| 3 | Medtronic | 117.20 Bn | 108.39 Bn | 6.34 Bn | -0.80% |
| 4 | Stryker | 104.01 Bn | 100.53 Bn | 4.50 Bn | 60.16% |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | -85.83% |
| 6 | Edwards Lifesciences | 49.80 Bn | 45.55 Bn | 1.35 Bn | 43.26% |
| 7 | Alcon | 33.03 Bn | 31.58 Bn | 1.68 Bn | 1.60% |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn | -26.30% |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn | 269.22% |
| 10 | Insulet | 9.35 Bn | 8.82 Bn | 562.60 Mn | 31.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.66% |
| Mar 31, 2026 | -63.29% |
| Dec 31, 2025 | 6.99% |
| Sep 30, 2025 | -176.63% |
| Jun 30, 2025 | -358.86% |
| Mar 31, 2025 | 82.00% |
| Dec 31, 2024 | 43.03% |
| Sep 30, 2024 | 163.80% |
| Jun 30, 2024 | 26.05% |
| Mar 31, 2024 | 37.05% |
| Dec 31, 2023 | -41.22% |
| Sep 30, 2023 | -22.71% |
| Jun 30, 2023 | -65.31% |
| Mar 31, 2023 | -80.05% |
| Dec 31, 2022 | 37.07% |
| Sep 30, 2022 | -60.28% |
| Jun 30, 2022 | 29.93% |
| Mar 31, 2022 | -92.97% |
| Dec 31, 2021 | -74.36% |
| Sep 30, 2021 | 34.52% |